<DOC>
	<DOCNO>NCT00118937</DOCNO>
	<brief_summary>Ninety percent patient type-1-diabetes develop late-diabetic complication eye , kidney , nervous- cardiovascular-system . Poor glycaemic control important risk-factor development late-diabetic complication . The Diabetes Control Complications Trial ( DCCT ) -study show , improved glycaemic control prevent development progression late-diabetic complication . Until treatment insulin- diet-therapy treatment-modalities available improve glycaemic control patient type-1-diabetes . A substantial number patient still long-standing poor glycaemic control despite intensive treatment insulin- diet-therapy . The antidiabetic drug metformin show able improve glycaemic control combination insulin furthermore reduce mortality risk develop cardiovascular disease patient type-2-diabetes . Only small study investigate effect treatment metformin patient type-1-diabetes . These study suggest positive effect metformin patient . Method : 100 patient type-1-diabetes persistent poor glycaemic control i.e . HbA1c &gt; 8.5 % last 12 month eligible . Patients treat one month placebo . Hereafter half patient treat metformin half continue placebo 12 month add-on therapy . All patient continue ongoing treatment insulin throughout study . Before start treatment metformin effect glycaemic control know risk-factors development cardiovascular disease i. e. blood-pressure , fast lipid , urine-albumine-excretion , endothelial dysfunction , inflammation , fibrinolysis etc . assess . This study show treatment metformin improve glycaemic control hereby prognosis patient type-1-diabetes persistent poor glycaemic control despite intensive treatment insulin- diet-therapy . This group patient suffer high risk develop late-diabetic complication reduce quality life life-expectancy consequence .</brief_summary>
	<brief_title>Effect Metformin Patients With Type-1 Diabetes With Inadequate Glycaemic Control Insulin Diet</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>HbA1c &gt; 8.5 % one year prior enrolment . Diabetesduration &gt; 5 year . Age onset diabetes &lt; 35 year Fasting Cpeptide &lt; 300 pmol/l Age &gt; 18 year enrolment . Clinical biochemical sign kidney , liver heartfailure . Other coexist serious morbidity , affect studyparticipation outcome study i.e . cancer . Known abuse medication alcohol Hypoglycaemia unawareness . Pregnancy plan pregnancy studyperiod .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>